LNTH Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its intent to acquire Life Molecular Imaging Ltd. (LMI) for $350 million ...

Tafamidis not only improves survival but also mitigates cardiac structural changes and functional declines, underscoring its ...

The FDA accepted Biogen and Eisai’s BLA for a subcutaneous administration of the anti-amyloid antibody Monday as the partners ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...

Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment ...

The findings, seen in people with and without signs of amyloid buildup in the brain, suggest that microvascular trouble may ...

Diabetes, a chronic condition that affects millions of people, may have a connection with Alzheimer's disease. Unofficially ...

Researchers at the University of Michigan found that 80 percent of participants with suspected dementia had not been told ...

It is anticipated that people with AD-specific pathologic alterations may develop dementia at different rates in the absence of disease-modifying treatments. Slow amyloid-β (Aβ) protein aggregation, ...

The agency expects to issue a decision by Aug. 31, and it is slated to decide on maintenance dosing for an intravenous form of the drug later this month.